In recent years, RRM2 has been implicated in tumor progression in many cancers, including breast cancer [33,34], ovarian endometriosis [35], retinoblastoma [36], renal cell carcinoma [37,38], oral squamous cell carcinoma [39], and prostate cancer [40]. Here, RRM2 is linked to prostate cancer.